CNPR Regulatory Compliance & Ethical Standards 5 — Questions and Answers
Question 1: The FDA's MedWatch program is primarily designed to:
- Approve new drug applications from manufacturers
- Collect voluntary adverse event reports from healthcare professionals and consumers (Correct answer)
- Monitor pharmaceutical sales representative activities in the field
- Regulate direct-to-consumer advertising on television
Correct answer: Collect voluntary adverse event reports from healthcare professionals and consumers
MedWatch is FDA's safety reporting program that allows healthcare professionals and patients to voluntarily report adverse events and product problems.
Question 2: A pharmaceutical rep is asked by a nurse practitioner to leave samples of a product for patients who the NP will not personally supervise. According to PDMA, the rep should:
- Leave samples since nurse practitioners have prescribing authority in many states (Correct answer)
- Refuse unless the supervising physician countersigns the sample receipt
- Leave samples only if the products are generics
- Confirm the NP has a DEA number before leaving any samples
Correct answer: Leave samples since nurse practitioners have prescribing authority in many states
PDMA allows samples to be given to practitioners licensed to prescribe the drug, and nurse practitioners with prescriptive authority qualify in states where they have that authority.
Question 3: Which of the following is a key distinction between an 'educational grant' and a prohibited kickback in pharmaceutical compliance?
- Educational grants must always be paid directly to the physician rather than their institution
- Legitimate educational grants are provided without expectation of prescribing activity and go through an independent process (Correct answer)
- Grants under $10,000 are automatically exempt from anti-kickback scrutiny
- Educational grants may only fund FDA-approved product training
Correct answer: Legitimate educational grants are provided without expectation of prescribing activity and go through an independent process
A legitimate educational grant is provided through an independent, arm's-length process with no strings attached to prescribing, while a kickback involves quid pro quo.
Question 4: State-level 'aggregate spend' or 'gift ban' laws that restrict pharmaceutical company interactions with physicians are:
- Preempted entirely by federal PhRMA guidelines and do not need to be followed
- In addition to federal requirements and may be more restrictive than federal law (Correct answer)
- Enforced exclusively by the FDA rather than state authorities
- Applicable only to companies headquartered in those states
Correct answer: In addition to federal requirements and may be more restrictive than federal law
Many states have enacted their own marketing transparency and gift restriction laws that apply independently of and can be more stringent than federal requirements.
Question 5: The term 'misbranding' as defined under the Food, Drug, and Cosmetic Act most directly applies to pharmaceutical promotion that:
- Uses a brand name that is trademarked by another company
- Contains false or misleading labeling or promotional claims about the drug (Correct answer)
- Fails to include the drug's generic name in the brand name typeface
- Does not display the NDC number prominently on packaging
Correct answer: Contains false or misleading labeling or promotional claims about the drug
Misbranding under the FDCA occurs when a drug's labeling (including promotional materials) is false, misleading, or fails to disclose required information.
Question 6: When a pharmaceutical representative discovers that a physician they call on is under a corporate integrity agreement restriction for past fraud, the appropriate action is to:
- Continue normal sales calls since the CIA only affects the physician's practice
- Immediately consult compliance to determine whether interactions with this physician are permissible (Correct answer)
- Avoid the physician entirely without notifying compliance
- Report the physician to the OIG directly
Correct answer: Immediately consult compliance to determine whether interactions with this physician are permissible
Interactions with excluded or CIA-restricted individuals can create liability; compliance must be consulted to assess whether and how the relationship may continue.
Question 7: The requirement for pharmaceutical companies to submit 'Dear Healthcare Provider' (DHCP) letters is typically triggered by:
- A new product launch requiring market awareness
- Important new safety information such as a label change or market withdrawal (Correct answer)
- Annual sales cycle reviews and territory realignment
- Voluntary educational initiatives above a certain budget threshold
Correct answer: Important new safety information such as a label change or market withdrawal
FDA may require or companies may issue DHCP letters to rapidly communicate important safety updates, label changes, or recall information to prescribers.
CNPR Regulatory Compliance & Ethical Standards 5
The FDA's MedWatch program is primarily designed to: